The private sector in Kinshasa, Democratic Republic of Congo (DRC), sells 86% of the city’s antimalarials, but offers inefficient monotherapies, artemisinin-based combination therapies (ACTs) of questionable quality and only few, expensive quality-assured ACTs (QAACTs).
To improve access to affordable QAACTs, in 2016 Population Services International (PSI) and Association de Santé Familiale (ASF) began facilitating the introduction of subsidized QAACTs bearing a ‘Green Leaf’ logo, distributed through existing supply chains. Supported by provider and consumer behavior change activities, these lower-cost QAACTs were expected to increase access to quality medicine and crowd out less effective treatments